https://www.selleckchem.com/pr....oducts/GSK872-GSK239
Quality of life improved during induction treatment, being clinically meaningful already after three induction cycles. Ixa-Dara-dex lead to a high response rate and improved quality of life. However, treatment discontinuation because of toxicity and early mortality, negatively influencing PFS and OS, remains a concern in frail patients. The outcome was heterogeneous across frail subpopulations. This should be taken into account in the design and interpretation of future studies in frail patients, to pave the way for more prec
Like
Comment
Share
